Dr. Jose F. Camargo Galvis, MD

Dr. Camargo Galvis practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Camargo Galvis' NPI, 1649686692, was assigned on July 9, 2014. Dr. Camargo Galvis graduated from Other in 2003. Dr. Camargo Galvis holds Florida license ME120778.

Dr. Camargo Galvis' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Camargo Galvis' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Camargo Galvis is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Camargo Galvis practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Camargo Galvis' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Camargo Galvis is board certified in infectious disease by the American Board of Internal Medicine. Dr. Camargo Galvis is licensed in Florida.

Dmand AI lists hiv/aids, immune deficiency disease and pneumonia among the conditions Dr. Camargo Galvis treats.

CMS data shows 235 Medicare services from Dr. Camargo Galvis across 5 procedure codes in 2024, for 93 Medicare patients. Medicare paid $23,119 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Camargo Galvis in 2024. The largest group is 65 to 74, with 35 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 44% are also on Medicaid. Their average risk score is 4.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Camargo Galvis' median patient age at 68, with 41% women.

In 2024, Dr. Camargo Galvis wrote 86 Medicare Part D claims for 15 patients. 66% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $71,725 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Camargo Galvis for performance year 2024, reported as part of a group. Dr. Camargo Galvis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Camargo Galvis as offering telehealth.

CMS Open Payments shows 8 general payments to Dr. Camargo Galvis from 2 drug and device companies from 2021 to 2024. Consulting fees make up the largest share, 51% of the total. Merck Sharp & Dohme Corporation paid the most, $12,670.

Dr. Camargo Galvis graduated from Other in 2003.

Dr. Camargo Galvis is in network with 11 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.